title: Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC).
authors.affiliation: Department of Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
authors.forename: R
authors.initials: R
authors.lastname: Wierzbicki
authors.forename: A
authors.initials: A
authors.lastname: Ezzat
authors.forename: A
authors.initials: A
authors.lastname: Abdel-Warith
authors.forename: A
authors.initials: A
authors.lastname: Ayoub
authors.forename: I
authors.initials: I
authors.lastname: Kagevi
authors.forename: M
authors.initials: M
authors.lastname: Fadda
authors.forename: J
authors.initials: J
authors.lastname: Sieck
authors.forename: M
authors.initials: M
authors.lastname: Abdulkareem
authors.forename: T
authors.initials: T
authors.lastname: Amin
authors.forename: A
authors.initials: A
authors.lastname: Yazigi
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D005047:Etoposide